Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, experimentation, industrialisation/scaling, adoption, and monetisation.
In the pharmaceutical research field, the journey from laboratory to pharmacy shelf is fraught with challenges, such as the high failure rates and increasing costs of clinical trials.
